ID Analysts

Our seasoned team of analysts continually monitors investment opportunities around the world, to provide investors with the widest possible array of money-making ideas.

Analyst Articles

We added two new positions last week, picking up shares of Amylin Pharmaceuticals (AMLN) after the stocks plunged following the US Food and Drug Administration’s request for another study is its revolutionary long-acting diabetes drug. We may have to hold the position for a couple of months, but we expect… Read More

Stocks are pausing today, led by pullbacks in tech giants Apple and International Business Machines, whose earnings/guidance came in light of some expectations, even though the for Apple the disappointment was only for iPad unit sales. Read More

We’re holding just three trades at this time. Gold miner Gabriel Resources (GBU.TO, GBRRF) is a buy. The only news on the company is that the CEO just bought 25,000 shares last week at an average price of C$5.75. That’s a vote a confidence we’re happy to see.   The… Read More

This has been a most unusual investment environment, to say the least. The recovery has been the weakest on record. And 16 months after the recession’s end the economic data coming in has been lackluster, at best. Commodity prices have soared in the past year on emerging market demand. These rising prices are a direct tax on consumers’ wallets. Read More

We closed out our Teva Pharmaceuticals (TEVA) December 18, 2010 50 call option for a gain of 21 percent last week as the stock’s rebound appeared to have stalled.  We’re still holding the Lockheed Martin December 18, 2010 Lockheed Martin (LMT) 70 call option.   Gold is taking… Read More

Stocks have been flirting with the psychologically important 1150 level on the S&P 500 for two weeks now, and traders may have to wait a while longer before we breakout above that resistance level, but it certainly is within reach.   Read More

In the meantime, we’re still holding the Lockheed Martin (LMT) December 18, 2010 70 call option and the Teva Pharmaceuticals (TEVA) December 18, 2010 50 call option, looking for them to advance further, although our patience with trades is wearing thin.   We heard more good news for… Read More